Welcome to our dedicated page for Quanterix SEC filings (Ticker: QTRX), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The Quanterix Corporation (NASDAQ: QTRX) SEC filings page on Stock Titan provides direct access to the company’s regulatory disclosures, along with AI‑supported context to help interpret them. As a life sciences and testing laboratories company focused on ultra-sensitive biomarker detection and spatial biology, Quanterix uses its SEC reports to describe its financial performance, corporate transactions, and governance decisions.
Key documents available here include Form 10‑K annual reports and Form 10‑Q quarterly reports, which outline revenue from product sales, service and other revenue, collaboration and license revenue, and grant revenue. These filings also discuss cost of goods sold, research and development expenses, selling, general and administrative expenses, and the use of non‑GAAP measures such as adjusted EBITDA, adjusted gross margin, and adjusted cash usage. AI summaries can highlight how these metrics relate to Quanterix’s Simoa platforms, Accelerator Laboratory services, and the integration of Akoya Biosciences.
Frequent Form 8‑K current reports document material events. Recent examples include announcements of quarterly financial results, the completion and pro forma impact of the Akoya acquisition, shareholder votes on declassifying the Board and eliminating supermajority voting requirements, and changes in Board composition. Our tools surface the main points of each 8‑K so readers can quickly understand what changed and why it matters for QTRX.
Investors can also review proxy statements referenced in the filings for details on director elections, executive compensation proposals, and governance changes, as well as any Form 4 insider transaction reports that may be filed separately. Real‑time updates from EDGAR ensure that new filings appear promptly, while AI‑generated explanations help translate technical accounting and legal language into more accessible summaries.
Use this page to explore Quanterix’s historical and current SEC filings, compare reporting periods, and understand how financial results, acquisitions, and governance actions are reflected in official disclosures.
Quanterix Corporation (QTRX) filed Post-Effective Amendment No. 3 on Form S-8 to its previously declared-effective Form S-4, completing the technical step needed to register shares that will be issued under equity awards assumed from Akoya Biosciences following the recently closed merger.
- Shares registered: 253,181 shares of Quanterix common stock, representing the maximum issuable upon vesting of outstanding Akoya restricted stock units ("Rollover RSUs").
- Merger exchange ratio: each Akoya share converted at closing into 0.1470 Quanterix share plus $0.37 cash.
- Total shares previously registered: 8,357,169 on the original Form S-4, covering stock consideration to Akoya shareholders and all equity awards; today’s filing carves out only the RSU component.
- Fees: all SEC filing fees were paid with the original Form S-4; no additional fees are due.
- Plan coverage: the amendment relates to the Akoya Biosciences 2015 & 2021 Equity Incentive Plans, now assumed by Quanterix.
- Rule 416(a) applicability: automatic coverage for share increases from stock splits, dividends, or similar corporate actions.
Part II of the filing reiterates standard incorporation by reference of recent Quanterix periodic reports, describes Delaware law-based indemnification provisions, and lists exhibits, including opinions from Covington & Burling LLP and auditor consents. The document is strictly administrative—no new financial results, guidance, or strategic changes are disclosed; its primary purpose is to ensure that shares underlying assumed Akoya equity awards are properly registered for issuance post-merger.
FAQ
What is the current stock price of Quanterix (QTRX)?
What is the market cap of Quanterix (QTRX)?
